Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Celcuity Announces Phase 3 VIKTORIA-1 Data: Gedatolisib Triplet Reduces Risk of Progression or Death by 76% in HR+/HER2- PIK3CA Wild-Type Advanced Breast Cancer

Author: Benzinga Newsdesk | October 20, 2025 03:16am

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups
Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ("gedatolisib triplet") and in 11.5% of patients treated with gedatolisib + fulvestrant ("gedatolisib doublet")
Study treatment discontinuation due to treatment related adverse events was reported in 2.3% of patients treated with the gedatolisib triplet and 3.1% of patients with the gedatolisib doublet
Management to host webcast and conference call October 20, 2025, at 8:00 a.m. ET

Posted In: CELC